J H M Schellens

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.

J. Schellens, J. Beijnen, I. Meijerman, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

J. Schellens, J. Beijnen, A. Huitema, 2011, International journal of pharmaceutics.

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

J. Schellens, S. Marchetti, J H M Schellens, 2007, British Journal of Cancer.

Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

J. Schellens, E. Voest, A. Bosma, 2012, Lung cancer.

Oral topotecan: bioavailability and effect of food co-administration

J. Schellens, H. Rosing, J. Beijnen, 1999, British Journal of Cancer.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

J. Schellens, J. Beijnen, F. Amant, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.